导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 7.76% | 858/4773 |
| 近一周 | -2.64% | 2743/5462 |
| 近一月 | -5.24% | 3119/5421 |
| 近一季 | -6.75% | 2185/5209 |
| 近半年 | -2.20% | 1816/4920 |
| 近一年 | 14.21% | 734/4366 |
| 近两年 | 89.05% | 697/2954 |
| 近三年 | 61.46% | 424/2253 |
| 成立以来 | 119.18% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
5.56% 379/4961 |
14.55% 1799/5312 |
- - |
- - |
| 2025 | 38.38% 870/4813 |
2.32% 1405/3635 |
3.13% 1147/4076 |
28.56% 1258/4524 |
2.00% 1113/4813 |
| 2024 | 14.24% 1064/3463 |
1.16% 895/2808 |
-1.32% 1037/3014 |
12.78% 2291/3129 |
1.48% 1065/3463 |
| 2023 | -11.07% 1368/2656 |
3.38% 1209/2280 |
-4.21% 1095/2385 |
-4.87% 1243/2515 |
-5.60% 1410/2655 |
| 2022 | -17.28% 569/2207 |
-8.38% 278/1919 |
1.34% 1485/2016 |
-9.19% 253/2113 |
-1.89% 1755/2208 |
| 2021 | 17.02% 250/1822 |
0.21% 309/1255 |
12.69% 320/1330 |
3.29% 412/1466 |
0.33% 1135/1822 |
| 2020 | 46.62% 208/1250 |
4.10% 88/1028 |
22.84% 196/1067 |
9.76% 628/1164 |
4.47% 838/1184 |
| 2019 | 33.85% 421/1092 |
28.78% 294/739 |
-5.59% 472/788 |
1.17% 426/850 |
8.82% 283/918 |
| 2018 | -24.06% 316/834 |
- - |
-8.45% 217/631 |
-6.61% 410/660 |
-10.92% 236/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 长信中证500指数增强A VS. 长安沪深300非周期A(740101) |